Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Aims to Give Society Access to Results of Research in Genomic Medicine: President
November 5, 2015
- Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
November 4, 2015
- PMDA Reviewing Opdivo for Risk of Type 1 Diabetes
November 4, 2015
- PAFSC 1st Committee Recommends Approval for Social Anxiety Disorder for Lexapro
November 4, 2015
- MHLW Weighs Another Business Improvement Order to Novartis
November 4, 2015
- Fiscal System Council Approves MOF’s Proposal for NHI Pricing System Reform
November 2, 2015
- MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
November 2, 2015
- Takeda’s Hib Vaccine to Be Reported to PAC in December
November 2, 2015
- PAFSC’s 2nd Committee Receives Report on Add’l Indication for Xeloda, Elplat
November 2, 2015
- MOF Asks Fiscal System Council to Issue Conclusion on Market Price Survey for FY2017 Revision “by Mid-2016 at Latest”
November 2, 2015
- 30% of Generic Companies Unable to Prepare Stable Supply Manuals by End of FY2014; MHLW Official Calls for Early Preparation
October 30, 2015
- Chuikyo Agrees to Tweak “Cost per Course of Treatment” Rule for Combo Drugs after Harvoni Debate
October 29, 2015
- Chuikyo Subcommittee Discusses Envisaged HTA Organization
October 29, 2015
- Chuikyo Sees Big Chorus for Further Reforms in Generic Pricing
October 29, 2015
- Some Chuikyo Subcommittee Members Call for Revision of Rules for Pricing of Biosimilars
October 29, 2015
- Commentary: 1st Sakigake Drugs Picked via “Comparative Evaluation”, Will All Qualified Products Get Designated in the Future?
October 28, 2015
- Thrombopenia Added to Clinically Significant ADR List for Daklinza, Sunvepra
October 28, 2015
- MHLW Eager to Expedite Commercialization of Sakigake Products: New Bureau Head
October 28, 2015
- Keytruda, Novel Anti-Flu Drug Join Japan’s First Sakigake Designation List
October 28, 2015
- MHLW to Talk with MIC about Local Tax Grants to Deal with Increased Costs of Flu Vaccines: Health Service Bureau Chief
October 28, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…